<DOC>
	<DOCNO>NCT00003674</DOCNO>
	<brief_summary>RATIONALE : Dalteparin may effective inhibit growth blood vessel tumor , decrease risk metastatic cancer , prevent formation blood clot , improve quality life treat patient advanced cancer respond previous treatment . It yet know standard therapy effective without dalteparin treating advance breast , lung , colorectal , prostate cancer . PURPOSE : Randomized double blinded phase III trial compare effectiveness standard therapy without dalteparin treat patient advance breast , lung , colorectal , prostate cancer respond previous chemotherapy hormone therapy .</brief_summary>
	<brief_title>Standard Therapy With Without Dalteparin Treating Patients With Advanced Breast , Lung , Colorectal , Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effect low molecular weight heparin ( dalteparin ) plus standard therapy versus standard therapy alone overall survival rate patient advance cancer . II . Compare toxic effect regimens effect quality life patient . III . Assess incidence symptomatic thrombotic event deep venous thrombosis ( DVT ) , pulmonary embolus ( PE ) , clot catheter patient . OUTLINE : This randomize study . Patients stratify accord prognostic index ( good v bad vs unsure ) , current therapy ( systemic v radiation v v none ) , age ( 50 vs 50 ) , disease site ( breast v colon v small cell lung vs nonsmall cell lung v prostate ) , history prior thrombotic event 1 year ago ( yes v ) , gender . Patients randomize receive low molecular weight heparin ( dalteparin ) plus standard therapy standard therapy alone .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven breast , lung , colorectal , prostate cancer fail prior chemotherapy hormone therapy No active CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3500/mm3 Platelet count least 150,000/mm3 Fibrinogen low limit normal Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Prothrombin time great 1.5 time ULN Active partial thromboplastin time great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Other : No history heparin associate thrombocytopenia At least 1 year since prior thromboembolic phenomenon deep venous thrombosis , pulmonary embolus , clot catheter No prior intolerance unfractionated low molecular weight heparin PRIOR CONCURRENT THERAPY : No concurrent anticoagulation therapy No concurrent enrollment systemic radiation therapy study ( therapy study allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>veno-occlusive disease</keyword>
</DOC>